Corpus callosum axonal injury in multiple sclerosis measured by proton magnetic resonance spectroscopic imaging.

BACKGROUND Axonal damage has been observed in normal-appearing white matter (NAWM) for patients with multiple sclerosis (MS). OBJECTIVES To investigate changes in brain metabolite ratios in a region of normal-appearing corpus callosum (CC) for patients with MS and to test its relationship to changes in other regions of NAWM. DESIGN AND METHODS Data were collected from 24 patients with MS and 15 control subjects. Two-dimensional proton magnetic resonance spectroscopic imaging was performed centered at the CC. Regions of interest from normal-appearing CC were manually segmented using anatomical images. The NAWM outside the CC region was segmented based on the signal intensity in T1- and T2-weighted images. RESULTS The N-acetylaspartate-creatine-phosphocreatine ratio was lower in both regions for patients with secondary progressive MS compared with the controls; the N-acetylaspartate-creatine-phosphocreatine was lower only in the normal-appearing CC region for patients with relapsing-remitting MS (P<.001) compared with the controls. The ratio of choline-containing compound compared with the creatine-phosphocreatine ratio was also lower in the region of normal-appearing CC for patients with relapsing-remitting MS (P =.003) compared with the controls. There was a correlation between the N-acetylaspartate-creatine-phosphocreatine ratio in the normal-appearing CC and T1 lesions (r = -0.53, P =.01) for all patients. CONCLUSIONS The CC was a more sensitive location for depicting axonal injury than other regions of NAWM. A correlation between the reduction of the N-acetylaspartate-creatine-phosphocreatine ratio in the normal-appearing CC and the T1 lesions may suggest that transection of axons in lesions may cause distant axonal damage and/or dysfunction that are expressed and more sensitively detectable in the CC.

[1]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[2]  P M Matthews,et al.  Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. , 1996, Brain : a journal of neurology.

[3]  P M Matthews,et al.  Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. , 1998, Brain : a journal of neurology.

[4]  P. Matthews,et al.  Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. , 2000, Brain : a journal of neurology.

[5]  G. Barker,et al.  Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrations , 2000, Journal of neurology, neurosurgery, and psychiatry.

[6]  D J Jenden,et al.  In vivo 1H MRS choline: correlation with in vitro chemistry/histology. , 1996, Life sciences.

[7]  P. Matthews,et al.  Imaging of axonal damage in multiple sclerosis: Spatial distribution of magnetic resonance imaging lesions , 1997, Annals of neurology.

[8]  P M Matthews,et al.  Imaging axonal damage of normal-appearing white matter in multiple sclerosis. , 1998, Brain : a journal of neurology.

[9]  Susan M. Chang,et al.  Volume MRI and MRSI techniques for the quantitation of treatment response in brain tumors: Presentation of a detailed case study , 1997, Journal of magnetic resonance imaging : JMRI.

[10]  P M Matthews,et al.  Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: Assessment of the load of disease , 1990, Magnetic resonance in medicine.

[11]  J Star-Lack,et al.  High spatial resolution 1H‐MRSI and segmented MRI of cortical gray matter and subcortical white matter in three regions of the human brain , 1999, Magnetic resonance in medicine.

[12]  C R Guttmann,et al.  A longitudinal study of callosal atrophy and interhemispheric dysfunction in relapsing-remitting multiple sclerosis. , 2001, Archives of neurology.

[13]  F. Di Salle,et al.  Proton MRS in neurological disorders. , 1999, European journal of radiology.

[14]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[15]  G. Barker,et al.  Proton MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis , 1999, Journal of the Neurological Sciences.

[16]  E. Cabanis,et al.  Localized proton magnetic resonance spectroscopy in relapsing remitting versus secondary progressive multiple sclerosis , 1999, Neurology.

[17]  R. Lenkinski,et al.  MR spectroscopy in the evaluation of enhancing lesions in the brain in multiple sclerosis. , 1996, AJNR. American journal of neuroradiology.

[18]  P M Matthews,et al.  Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. , 2001, Archives of neurology.

[19]  J. Coyle,et al.  Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies , 1991, Neuroscience.

[20]  Geoff J. M. Parker,et al.  1H Magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis , 1999, Journal of Neurology.

[21]  J. Kurtzke Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[22]  S. Nelson Analysis of volume MRI and MR spectroscopic imaging data for the evaluation of patients with brain tumors , 2001, Magnetic resonance in medicine.

[23]  R. Tarducci,et al.  Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients. , 1999, Brain : a journal of neurology.

[24]  S. Nelson,et al.  3-D echo planar (1)HMRS imaging in MS: metabolite comparison from supratentorial vs. central brain. , 2002, Magnetic resonance imaging.